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Abstract
Background: Most patients with childhood non-organic growth hormone (GH) deficiency (GHD)
produce a normal GH peak as young adults. Our objectives were to better define this transient
GHD and evaluate the factors influencing the growth response of patients with pituitary stalk
interruption syndrome (PSIS).
Methods: We studied 72 prepubertal patients with a GH peak < 6.7 ng/ml after 2 stimulation tests,
treated with 0.2 mg GH/kg/w for at least 3 years. Group 1 (n = 53, 4.7 ± 4.0 years) had PSIS and
Group 2 (n = 19, 9.2 ± 3.0 years) had transient GHD and normal pituitary.
Results: At diagnosis, 64% of Group 1 and one Group 2 were < 5 years old. The growth rate of
59% Group 1 and two Group 2 patients was ≤ -2 SDS. The GH peak of 64% Group 1 patients and
no Group 2 patients was < 3 ng/ml. The plasma insulin-like growth factor-1 of all Group 1 and all
but one Group 2 patients was ≤ -2 z scores.
During the first year of GH treatment, the growth rate was ≥ 2 SDS in 81% Group 1 and 37%
Group 2 patients. In Group 1, it was negatively correlated with the GH peak before treatment (P
< 0.03), and with the difference between the target and adult heights (P < 0.01).
The height gain SDSs between diagnosis and adult height were 1.7 ± 1.2 in Group 1 (n = 30) and
1.08 ± 0.8 in Group 2 (n = 12, P = 0.05).
Conclusion: The factors of the growth response to GH treatment should be analysed separately
for each population: with and without PSIS or other markers.
Background
Growth hormone (GH) deficiency (GHD) due to damage
to the hypothalamic-pituitary region by lesions, surgery
and/or radiation is said to be "organic". In other circum-
stances, GHD is readily diagnosed when magnetic reso-
nance imaging (MRI) shows pituitary stalk interruption
syndrome (PSIS) [1] and/or if there is microphallus,
hypoglycemia, other hypothalamic-pituitary deficiencies,
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or genetic causes. GHD is difficult to diagnose when none
of these conditions apply, the GHD is then said to be "idi-
opathic".
GHD is diagnosed by the height of the GH peak after
pharmacological stimulation. The value of these tests has
been questioned [2] because they are expensive, labor
intensive, occasionally risky, and their results are not very
reproducible. The majority of patients who have no mark-
ers of certain GHD produce a normal GH peak response
to these tests when evaluated as young adults [3]. The
growth rate and plasma insulin-like growth factor (IGF) 1
concentration of these patients with "transient" GHD are
frequently low for their chronological age at diagnosis [4].
The question is whether the transient GHD reflects a true
transient decrease in GH secretion or an insufficient
response to the stimulation test, as occurs in many short
or normal height, non-GHD patients [5]. The transient
GHD may be partly responsible for the variability of the
growth response to GH treatment.
We compared the characteristics at diagnosis, growth dur-
ing the three first years of GH treatment, and adult height
and concomitant GH evaluation of patients with GHD
and PSIS to patients with transient GHD. Our first objec-
tive was to analyze the characteristics of transient GHD
and compare them to that of a permanent GHD group,
that with PSIS; our second objective was to evaluate the
factors influencing the growth response of patients with
PSIS.
Methods
Patients
The subjects of this retrospective longitudinal study were
72 consecutive prepubertal patients with GHD first seen
by one of us (R. Brauner) in a university pediatric hospital.
They were first seen from birth to 17 years, and treated
with GH for at least 3 years.
Group 1 included 53 patients with GHD and PSIS. Fifteen
other patients seen during the same period were not
included because the PSIS was associated with malforma-
tive syndrome, which can modify the parameters studied
(Fanconi anemia n = 6, Blackfan-Diamond anemia n = 1),
or because their GH treatment was initiated elsewhere (n
= 8).
Group 2 included 19 patients with transient GHD, ini-
tially diagnosed as having isolated idiopathic GHD
because of a low GH peak after two stimulation tests and
a normal pituitary on MRI. They were treated with GH and
produced a normal GH peak after a third stimulation test.
None of them had intrauterine growth retardation, meta-
bolic disease or malformative syndrome.
The other patients treated during the same period for idi-
opathic GHD without PSIS or a demonstrated transient
character were not included.
Protocol
Informed consent for the evaluations and treatments was
obtained from the children's parents. The Ethical Review
Committee (Comité de Protection des Personnes Ile de
France III) stated that "this research was found to conform
to generally accepted scientific principles and research
ethical standards and to be in conformity with the laws
and regulations of the country in which the research
experiment was performed".
The criterion for diagnosing GHD was a GH peak
response of less than 6.7 ng/ml after two pharmacological
stimulation tests, excluding the GH-releasing hormone
test.
The first evaluation was performed in a single morning
after an overnight fast, and included measurements of
height and weight, bone age (except in those aged less
than one year), a pharmacological stimulation test of GH
secretion, and checks to exclude other causes of short stat-
ure. As the GH peak at the first test was subnormal, a sec-
ond test using another stimulus was performed. As this
second test also showed a subnormal GH peak, the pro-
gram included MRI to exclude organic intracranial lesions
and to look for PSIS, and evaluation of the other pituitary
functions.
The replacement treatment for Group 1 patients included
thyroxin (3–5 μg/kg/day) for 29 of them with thyroid
stimulating hormone (TSH) deficiency, and hydrocorti-
sone (6–17 mg/m2/day) for 23 of them with adrenocorti-
cotropin deficiency. Thirty six patients reached pubertal
age. The 15 of them who had no pubertal development
despite being of pubertal chronological and bone ages
underwent a gonadotropin releasing hormone stimula-
tion test. It showed gonadotropin deficiency; the girls
were given oral ethinyl estradiol (2 μg/day) from the age
of about 12 years, and the boys were given testosterone
heptylate (25 mg i.m. every 14 days) from around 13–14
years. These doses were continued during the growing
period and increased to the adult dose when growth had
ceased.
The patients on replacement treatment were seen every 3
(younger than 2 years) or 6 months to measure their
height, weight and to adjust the GH, thyroxin and hydro-
cortisone doses for their weight, clinical features and, if
necessary, plasma free thyroxin concentrations.
GH treatment was stopped when the height increase over
the six previous months was less than 1 cm with a boneBMC Pediatrics 2009, 9:29 http://www.biomedcentral.com/1471-2431/9/29
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age greater than 15 years (boys) or 14 years (girls). Group
1 patients were treated for 9.9 years and Group 2 patients
for 5.4 years (P < 0.0001), but the GH doses were similar
(0.2 and 0.19 mg/kg/w). A third stimulation test was per-
formed on 25 Group 1 patients and all Group 2 patients
at least one month after the end of GH treatment. Adult
height was reached by 30 Group 1 and 12 Group 2
patients.
Methods
Height was measured twice with a Harpenden stadiome-
ter. The height, growth rate and body mass index (BMI,
weight in kg/height in m2) are expressed as standard devi-
ation scores (SDS) for chronological age [6,7]. The growth
rate before treatment of 6 patients aged less than one year
at diagnosis was not calculated. The growth rates of the 4
patients of pubertal age but prepubertal stage were com-
pared to the prepubertal values. Target height was calcu-
lated from parental heights [8] except for 4 adopted
patients. Bone age was assessed by R. Brauner [9].
The results of GH treatment are expressed as the SDSs of
the growth rates each year and the height changes each
year and over 3 years of treatment, and of the adult height.
They were compared in each group to the data at the start
of GH treatment: chronological and bone ages and their
difference, height, difference from target height, growth
rate, BMI, GH peak, IGF-1 and with GH dose. The growth
rate was also compared to the change in BMI during the
same period and to the growth rate the previous year. In
the Group 1, the patients with isolated GHD were com-
pared to those having additional deficiencies, substituted
with thyroxin and hydrocortisone. None of them were
given sex steroids during the first three years of treatment.
GH secretion was assessed at diagnosis by the sequential
arginine-insulin test and the ornithine test; a glucagon test
was used for patients weighing less than 10 kg and those
who were hypoglycemic. As the mean GH peak heights for
the first and second pharmacological stimulation tests
performed before GH treatment in each group were not
different and as these evaluations were very similar, the
larger GH peak and the concomitant plasma IGF-1 values
were used for analysis. The third test used stimulation by
arginine-insulin or glucagon.
GH was measured over the years using several different
immunoassays calibrated against different reference prep-
arations. The GH peaks were therefore recalculated to
express them in ng/ml of the international reference
standard 98/574 (recombinant 22 kDa GH, 1 μg = 3 mU),
as requested in a recent consensus on GH assays [10]. We
used the DiaSorin RIA competive assay (DiaSorin, Sallu-
gia, Italy), calibrated against the 66/217 reference (1 μg =
2 mIU), the Immunotech IRMA kit (Immunotech, Mar-
seille, France), calibrated against the 80/505 international
standard (1 μg = 2.6 mIU), and most recently the Beck-
man-Coulter Access automated immunochemilumiscent
assay (Beckman-Coulter, Chaska, Minnesota), now cali-
brated against the new 98/574 reference preparation
(recombinant hGH, 1 μg = 3 mIU). As the results of these
3 assays were very similar when expressed in mU/l, we
multiplied the results in μg/l (= ng/ml) obtained with the
DiaSorin and the Immunotech assays by 2 and 2.6 respec-
tively and then, for all the assays, divided the calculated
results in mIU/l by 3.
IGF-1 was measured by immunoassay (IGF-1-RIACT, Cis
Bio, Gif sur Yvette, France) and expressed in Zscore (zs)
according to chronological age [11]. The control group at
the first evaluation included normal prepubertal children,
and at the third evaluation it included 31 adolescents aged
14–16 years and 30 young adults aged 17–20 years of nor-
mal height and weight and spontaneous pubertal devel-
opment.
Other pituitary functions were evaluated by basal blood
cortisol at 08.00 h, thyroxin, prolactin, and the TSH
response to thyrotropin releasing hormone; the plasma
and urinary osmolalities after water deprivation for 12-h
were normal in all patients.
Data are expressed as means ± SD. Groups were compared
with a Mann-Whitney U test. Correlations were analyzed
using Spearman's test.
Results
1. Characteristics at diagnosis (Table 1 and Figure 1)
Group 1: one girl had a paternal aunt with PSIS. Micro-
phallus was present in 11/31 (35.5%) boys and cryp-
torchidism in 6/31 (20%) boys; 24/53 (45.3%) patients
suffered from hypoglycemia and 29 (54.7%) had other
hypothalamic-pituitary deficiencies. Among these, 4 had
only a TSH deficiency, 10 had TSH and adrenocorticotro-
pin hormone deficiencies, 2 had TSH and gonadotropin
deficiencies, and 13 had a complete anterior pituitary
deficiency.
Group 2: four of them had anterior pituitary hypoplasia
(height < 4 mm, – 2 SD for chronological age) [1]
The sex ratio, height and weight at birth, height, difference
between target and actual heights, BMI, plasma IGF-1 and
difference between chronological and bone ages were
similar in the two groups, but the patients with PSIS were
significantly younger at diagnosis, and had greater target
heights, slower growth rates and lower GH peaks than
those with transient GHD.BMC Pediatrics 2009, 9:29 http://www.biomedcentral.com/1471-2431/9/29
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Characteristics at diagnosis Figure 1
Characteristics at diagnosis.
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Table 1: Patient characteristics
Group N (boys/girls) Age years
(a)
Height SDS Target height SDS
(b)
Growth rate SDS
(c)
BMI SDS GH peak ng/ml
(a)
IGF-1 zs
1. GHD with PSIS 53 (31/22) 4.7 ± 4.0
[0.02;17]
-2.5 ± 1.4
[-6.2; 0.8]
-0.2 ± 0.8
[-1.7;1.5]
-2.2 ± 1.4
[-4.3;1.6]
0.19 ± 1.7
[-2.4;6.7]
2.6 ± 1.8
0.0;6.6
-3.8 ± 0.9
-5.5;-2.3
2. Transient GHD 19 (9/10) 9.2 ± 3.0
[1.1;14.0]
-2.8 ± 0.8
[-4.4;-1.5]
-0.8 ± 0.9
[-2.6;0.9]
-1.2 ± 1.0
[-3.5;0.1]
0.32 ± 1.4
[-1.9;3.5]
4.9 ± 1.2
3.0;6.7
-3.2 ± 0.9
-4.8;-1.8
means ± SD [ranges]
Group 1 compared to Group 2: (a) P < 0.0001; (b) P < 0.02; (c) < 0.003
Among the 29 Group 1 patients with other hypothalamic-pituitary deficiencies, 4 had only a TSH deficiency, 10 had TSH and adrenocorticotropin 
hormone deficiencies, 2 had TSH and gonadotropin deficiencies, and 13 had a complete anterior pituitary deficiency.
Growth rates before and during the first three years of GH treatment Figure 2
Growth rates before and during the first three years of GH treatment.
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Thus the age at diagnosis of GHD was less than one year
in 6 Group 1 patients (including 5 aged less than one
month), but in no Group 2 patients. It was less than 5
years in 34 (64%) Group 1 patients and in one Group 2
patient.
The growth rate was below the mean in 93.5% of the
Group 1 patients and in 84.2% of the Group 2 patients.
The 3 Group 1 patients with a growth rate above the mean
included one born prematurely who underwent catch-up
growth and another with a BMI of 6.2 SDS. The growth
rate was ≤ -2 SDS in 59% of Group 1 patients and in two
Group 2 patients.
The GH peak was below 3 ng/ml in 64% of Group 1
patients, but in no Group 2 patient. The corresponding
percentages for a GH peak below 5 ng/ml were 90.4 and
63.1. The plasma IGF-1 was ≤ -2 zs in all Group 1 patients
and in all but one (-1.8) Group 2 patients.
2. Growth rates on treatment (Table 2, Figures 2 and 3)
The growth rates and the height changes of Group 1
patients were significantly greater than those of Group 2
patients during the first and second years of treatment, but
not during the third. The height changes over three years
were also greater in Group 1 than in Group 2. In Group 1,
the growth rates each year and over three years were simi-
lar in the patients with isolated GHD to those having
additional deficiencies.
The growth rate during the first year was ≥ 2 SDS in 81%
of Group 1 patients and in 36.8% of Group 2 patients. The
9 Group 1 patients with growth rate < 2 SDS included
three who were the oldest in the study. Their GHD was
diagnosed between 14 and 17 years; their growth rates
were compared to prepubertal values (see Methods). The
6 others, including 3 neonates, had hypoglycemia and
adrenocorticotropin hormone deficiency and were treated
with hydrocortisone (10–15 mg/m2/day). All had TSH
deficiency and were treated with thyroxin (4 to 5 μg/kg/
day).
Annual changes in height during the first three years of GH treatment Figure 3
Annual changes in height during the first three years of GH treatment.
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The height change during the first year was ≥ 1 SDS in
62.5% of the Group 1 patients and in one Group 2
patient.
3. Evaluation at the end of growth and adult height
The adult height SDSs were -1 ± 0.9 in Group 1 and -1.8 ±
0.8 in Group 2 (P<0.02, Table 2): 171.5 cm for the boys
and 155.8 cm for the girls in Group 1, and 162.7 (boys)
and 155 cm (girls) in Group 2.
The GH peaks were 2.3 ± 2.9 ng/ml for the Group 1 and
14.7 ± 11.4 ng/ml for the Group 2 patients (P < 0.0001).
The corresponding plasma IGF-1 concentrations were -3.6
± 1.2 and -1.4 ± 1.3 zs (P < 0.0008). These concentrations
were < -2 zs in all Group 1 patients and in 3/9 of the
Group 2 patients. They were positively correlated with the
GH peak for the whole population (P = 0.0002), but not
within each group.
4. Correlation
Group 1: the growth rate during the first year of treatment
was positively correlated with the BMI (P < 0.007) and
negatively with the GH peak before treatment (P < 0.03).
These correlations persisted when the 6 patients aged less
than one year at diagnosis were excluded. The adult height
SDS was positively correlated with the growth rate during
the second year of treatment (P < 0.03) and with the target
height (P < 0.01). The height gain between diagnosis and
the adult height (1.7 ± 1.2 SDS) was negatively correlated
with the height (P < 0.007) and positively correlated with
the difference between the chronological and bone ages
(P = 0.01) before treatment. The difference between the
target and adult heights (0.7 ± 0.8 SDS) was negatively
correlated with the growth rates during the first and third
years (P < 0.01 for both).
Group 2: the growth rates and the height change over 3
years were not correlated with the parameters before treat-
ment. The adult height SDS was positively correlated with
the target height (P < 0.03).
Discussion
This study shows that the patients with transient GHD
have features that differ from those of patients with PSIS.
In these, the growth rate during the first year on GH is neg-
atively correlated with the GH peak before treatment,
quantifying the degree of GHD, and with the difference
between the target and adult heights. The young patients
treated with hydrocortisone for symptomatic hypoglyc-
emia had a lower growth response.
1. Characteristics of transient GHD
It was difficult to decide whether the Group 2 patients had
a true transient decrease in their GH secretion or simply
an insufficient response to the stimulation test. The
majority had a growth rate below the mean and all but
one had a plasma IGF-1 concentration < -2 zs at diagnosis.
Their transient GHD is not explained by their BMIs being
different from those of the PSIS patients, or by pubertal
delay. One third of them had a growth rate of ≥ 2 SDS on
GH treatment. And while their GH peak at the end of
treatment was normal, 3/9 of them still had an IGF-1 of <
Table 2: The growth responses (SDS) of patients with PSIS or transient GHD to GH treatment
SDS PSIS Transient GHD P
(n = 53) (n = 19)
First year
Growth rate 3.8 ± 2.6 1.3 ± 2.2 0.0007
Height change 1.2 ± 1.0 0.48 ± 0.7 <0.0001
Second year
Growth rate 1.8 ± 2.4 0.26 ± 1.3 0.006
Height change 0.47 ± 0.5 0.18 ± 0.3 <0.03
Third year
Growth rate 0.77 ± 1.7 0.05 ± 1.3 NS
Height change 0.2 ± 0.4 0.14 ± 0.3 NS
Height change over three years 1.9 ± 1.1 0.8 ± 1.0 0.0002
(n = 30) (n = 12)
Adult height -1.0 ± 0.9 -1.8 ± 0.8 <0.02
Height change from diagnosis 1.7 ± 1.2 1.08 ± 0.8 0.05
Mean ± SDBMC Pediatrics 2009, 9:29 http://www.biomedcentral.com/1471-2431/9/29
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-2 zs. Their growth in response to GH treatment was not
correlated with their characteristics before treatment;
however, this might be because their number is smaller
than the Group 1 patients, while their different character-
istics before treatment may have contributed to their
lower growth response. The only correlation was between
their adult and target heights. Their height gain SDSs
between diagnosis and the adult height were lower than
those of the patients with PSIS, but the difference is not
significant.
We used logical data analysis, a combinatorial method
that produces rules characterististic of subsets of either
positive (patients with PSIS) or negative (patients with
short stature and normal GH peak) patients [12]. We find
that 74% of the patients with transient GHD were "in
between" the positive and negative patients, while 26%
were classified as negative.
Loche et al [13] found a normal GH peak in 28/33
patients having such characteristics, at a third evaluation
performed after 1 to 6 months without GH treatment.
2. Factors influencing the growth response of PSIS patients
The published analyses of the factors influencing the
growth response of GHD patients to GH treatment have
probably been hampered by the inclusion of patients with
transient GHD. Only three studies analysed patients with
congenital hypothalamic-pituitary MRI abnormalities
separately [14-16]. Zenaty et al [15] found the mean
height gain of 32 patients with MRI abnormalities to be
(2.2 SDS) after 3 years on 0.18 mg GH/kg/w, significantly
greater than that of 37 patients without such abnormali-
ties (1.6 SDS). Our results for the 47 patients with PSIS are
similar, after exclusion of the 6 aged less than one year.
Coutant et al [14] found that 15 patients with MRI abnor-
malities were significantly younger and shorter at diagno-
sis than 48 patients without such abnormalities; their
height gain between diagnosis and the adult height on
0.15 mg GH/kg/w was greater (2.7 SDS) than that of
patients without abnormalities (1.3 SDS) and their adult
height was greater (-1.1 SDS compared to -1.7 SDS).
When the patients without MRI abnormalities were
retested, 22/35 of them had a GH peak of ≥ 10 ng/ml. We
found similar adult heights, but the height gain for the
PSIS patients was less (1.7 SDS), probably because our
patients were younger and taller at diagnosis. This gain
was negatively correlated with their height and positively
correlated with the difference between the chronological
and bone ages before treatment. Maghnie et al [16]
reported the adult heights of 88 patients with permanent
GHD; 73 of them had MRI abnormalities and were treated
with 0.2 mg GH/kg/w. The heights of those with sponta-
neous and induced puberty were similar and the differ-
ence between the target and adult heights was around 0.4
SDS, while we found 0.7 SDS.
The growth during the first year of GH treatment has been
reported to predict the adult height [17-19]. We find that
the growth rate during the first year on GH is negatively
correlated with the difference between the target and adult
heights and with the GH peak before treatment, as did
Cole et al [20]. They found that the strongest predictor of
the first year growth response, adjusting for age, height,
weight, target height and injection frequency, was the GH
test result, suggesting that the growth response is the gold
standard for quantifying the degree of GHD. Van den
Broeck et al [21] showed that patients with severe GHD (a
GH peak < 5 ng/ml) responded better to treatment, but
that the responses of children with partial GHD and those
with idiopathic short stature were similar. Wilson et al
[22] found that all but the very lowest GH peaks were
poor predictors of subsequent growth. Bright et al [23]
reported that GH stimulation tests correctly identified
64% of the GH treatment outcomes: the increase in height
during the first year was greater than 0.5 SDS in 56% of
the patients with a GH peak <10 ng/ml, while it was less
than 0.5 SDS in 8% of those with a GH peak > 10 ng/ml.
Our data show that patients aged less than one year may
have an insufficient growth response despite PSIS,
because severe hypoglycemia with associated adrenocorti-
cotropin deficiency may lead to the use of slightly high
hydrocortisone replacement doses.
Conclusion
Our current policy for those patients who have a low GH
response to a stimulation test and normal MRI is to eval-
uate the clinical efficacy of GH therapy during the first two
years. If their growth rate does not increase significantly,
we propose a third evaluation of their GH secretion, after
interrupting GH treatment for at least one month.
The factors influencing the growth response to GH treat-
ment and the associated models should be analysed sepa-
rately for each of the populations: with and without PSIS
or other marker.
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